Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: The invention provides a compound represented by structural formula (I) or formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPKl activity.

Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

Abstract: Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.

Abstract: Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.

Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.

Abstract: The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

Abstract: A method for blockchain payment channel network multi-path routing based on a genetic algorithm includes: S1, constructing a directed graph according to a structure of a payment channel network; S2, based on the payment channel network, generating an initial population; S3, taking a total fee charge of the k payment paths corresponding to the each individual as an adaptability, and selecting a parent based on the adaptability; S4, based on the adaptability, performing a cross operation and a mutation operation on the parent; S5, when a population converges or a number of iterations reaches a preset threshold, determining the total fee charge for the each individual in a last-generation population, and selecting an individual with the smallest total fee charge as an optimal solution under a current k value; and, S6, selecting a target payment path from a plurality of selected payment paths.

Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.

Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.

Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

Abstract: A terminal component is applied to a speaker, and includes two terminals, a sleeve seat, and two fixing heads. Each terminal includes a terminal head and a terminal body. The sleeve seat includes two terminal blocks. The two terminal blocks respectively accommodate the two terminal bodies, so that the two terminal heads are exposed outside the sleeve seat. The two fixing heads are respectively combined with the two terminal heads, to respectively fasten two wires to the two terminals.

Abstract: An electronic device and an information processing method are provided. The electronic device includes: a maintaining body configured to maintain a relative position relationship between the electronic device and the at least one part of the body of the user in a case that the electronic device is in a maintained state; a display connected to the maintaining body and including at least two display regions; a first sensor configured to sense a motion parameter of the at least one part of the body in a case that the at least one part of the body of the user moves; and a processor configured to determine a motion state of the at least one part of the body based on the motion parameter and adjust a display mode of the display based on the motion state according to a first adjusting strategy.

Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.